Segment information (Tables)

12 Months Ended

Dec. 31, 2025

Segment information

Summary of segment information

The segment information for the financial year 2025 is as follows:


		Discovery &
		Preclinical		Just - Evotec		Intersegment		Evotec
in k€		Development		Biologics		eliminations		Group
Revenue*		528,930		259,443		—		788,373
Intersegment revenue		352		144		(496)		—
Cost of revenue		(482,470)		(192,161)		479		(674,152)
Gross profit		46,811		67,426		(17)		114,221
Operating income and (expenses)
Research and development		(37,454)		(72)		17		(37,509)
Selling, general and administrative expenses		(133,248)		(42,722)		—		(175,970)
Other operating income		61,370		4,230		—		65,599
Other operating expenses		(11,327)		(10,597)		—		(21,924)
Reorganization costs		(633)		—		—		(633)
Total operating income (expenses)		(121,294)		(49,161)		17		(170,438)
Operating income (loss)**		(74,482)		18,265		—		(56,217)

*Includes Revenue from contributions of €11,294k

**Includes €65,291k of depreciation and €9,478k of amortization related to D&PD and includes €24,707k of depreciation and €-k of amortization related to JEB

The segment information for the financial year 2024 is as follows:


		Discovery &
		Preclinical		Just - Evotec		Intersegment		Evotec
in k€		Development		Biologics		eliminations		Group
Revenue*		611,394		185,573		—		796,967
Intersegment revenue		160		1,049		(1,208)		—
Cost of revenue		(509,361)		(173,068)		344		(682,086)
Gross profit		102,192		13,553		(865)		114,881
Operating income and (expenses)
Research and development		(51,146)		(576)		865		(50,857)
Selling, general and administrative expenses		(158,915)		(29,286)		—		(188,201)
Other operating income		49,802		2,899		—		52,700
Other operating expenses		(13,924)		(2,192)		—		(16,116)
Reorganization costs		(54,179)		(751)		—		(54,930)
Total operating income (expenses)		(228,362)		(29,906)		865		(257,403)
Operating income (loss)**		(126,170)		(16,353)		—		(142,522)

*Includes Revenue from contributions of €14,450k

**Includes €70,753k of depreciation and €6,484k of amortization related to D&PD and includes €24,404k of depreciation and €-k of amortization related to JEB

The segment information for the financial year 2023 is as follows:


		Discovery &
		Preclinical		Just - Evotec		Intersegment		Evotec
in k€		Development		Biologics		eliminations		Group
Revenue*		672,977		108,449		—		781,426
Intersegment revenue		—		—		—		—
Cost of revenue		(492,674)		(113,701)		—		(606,375)
Gross profit		180,303		(5,252)		—		175,051
Operating income and (expenses)
Research and development		(68,529)		—		—		(68,529)
Selling, general and administrative expenses		(143,167)		(26,442)		—		(169,610)
Impairment/Reversal of impairment of intangible assets		108		(5,119)		—		(5,011)
Other operating income		62,524		2,269		—		64,793
Other operating expenses		(39,361)		(4,841)		—		(44,202)
Reorganization costs		—		—		—		—
Total operating income (expenses)		(188,425)		(34,133)		—		(222,558)
Operating income (loss)**		(8,122)		(39,385)		—		(47,507)

*Includes Revenue from contributions of €9,417k

**Includes €64,349k of depreciation and €6,946k of amortization related to D&PD and includes €21,685k of depreciation and €-k of amortization related to JEB

Summary of geographical breakdown

The geographical breakdown of revenue from customers for the financial year 2025 is stated below:


		Discovery &
		Preclinical		Just - Evotec
in k€		Development		Biologics		Evotec Group
Revenue by region
USA		323,508		108,001		431,509
Germany		25,293		—		25,293
France		19,783		72		19,855
United Kingdom		61,724		—		61,724
Switzerland		10,892		150,721		161,613
Rest of the world		76,436		649		77,085
Total revenue from contracts with customers		517,636		259,443		777,079
Revenue from contributions		11,294		—		11,294
Total Revenue		528,930		259,443		788,373

The geographical breakdown of revenue from customers for the financial year 2024 is stated below:


		Discovery &
		Preclinical		Just - Evotec
in k€		Development		Biologics		Evotec Group
Revenue by region
USA		354,124		91,735		445,859
Germany		32,904		—		32,904
France		19,910		—		19,910
United Kingdom		92,437		80		92,517
Switzerland		18,048		90,995		109,043
Rest of the world		81,662		621		82,283
Total revenue from contracts with customers		599,086		183,431		782,517
Revenue from contributions		12,308		2,142		14,450
Total Revenue		611,394		185,573		796,967

The geographical breakdown of revenue from customers for the financial year 2023 is stated below:


		Discovery &
		Preclinical		Just - Evotec
in k€		Development		Biologics		Evotec Group
Revenue by region
USA		414,192		45,232		459,424
Germany		29,297		4,837		34,134
France		32,005		—		32,005
United Kingdom		86,368		—		86,368
Switzerland		7,500		57,424		64,924
Rest of the world		95,154		—		95,154
Total revenue from contracts with customers		664,516		107,493		772,009
Revenue from contributions		8,461		956		9,417
Total Revenue		672,977		108,449		781,426

Non-current assets categorized by the location of the companies as of December 31, 2025 and December 31, 2024 can be analyzed as follows:


in k€		2025		2024
USA		216,421		257,861
United Kingdom		180,577		208,907
Italy		230,258		240,450
France		89,704		325,974
Germany		188,451		154,543
Total non-current assets		905,411		1,187,735